IE59204B1 - Antibiotics - Google Patents
AntibioticsInfo
- Publication number
- IE59204B1 IE59204B1 IE228086A IE228086A IE59204B1 IE 59204 B1 IE59204 B1 IE 59204B1 IE 228086 A IE228086 A IE 228086A IE 228086 A IE228086 A IE 228086A IE 59204 B1 IE59204 B1 IE 59204B1
- Authority
- IE
- Ireland
- Prior art keywords
- bbm
- exhibiting
- antibiotic
- spectrum
- antitumor
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title description 26
- 229940088710 antibiotic agent Drugs 0.000 title description 26
- 239000000126 substance Substances 0.000 claims abstract description 48
- 239000003972 antineoplastic antibiotic Substances 0.000 claims abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- 238000001228 spectrum Methods 0.000 claims description 23
- 230000001747 exhibiting effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 230000000259 anti-tumor effect Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 230000003115 biocidal effect Effects 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 16
- 229910002027 silica gel Inorganic materials 0.000 claims description 16
- 238000004809 thin layer chromatography Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 238000000862 absorption spectrum Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 238000001819 mass spectrum Methods 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 7
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001793 charged compounds Chemical class 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000012429 reaction media Substances 0.000 claims 5
- 238000011084 recovery Methods 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 229940072293 axid Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims 1
- 150000003613 toluenes Chemical class 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 18
- 230000000975 bioactive effect Effects 0.000 abstract description 15
- 241000201778 Actinomadura verrucosospora Species 0.000 abstract description 7
- 230000007073 chemical hydrolysis Effects 0.000 abstract description 7
- PEIYAHAOJOISPN-WCXFNBEESA-N [(2s,3s,4s,6s)-4-hydroxy-6-[[(5z,13e)-9-hydroxy-2-[(2s,3s,4r,5r,6s)-4-hydroxy-5-[[(2r,4r,5r,6s)-4-hydroxy-6-methyl-5-methylsulfanyloxan-2-yl]oxyamino]-3-[(2s,4s,5s)-4-methoxy-5-(propan-2-ylamino)oxan-2-yl]oxy-6-methyloxan-2-yl]oxy-12-(methoxycarbonylamino Chemical compound O1C[C@H](NC(C)C)[C@@H](OC)C[C@@H]1O[C@H]1[C@H](O)[C@@H](NO[C@H]2O[C@@H](C)[C@H](SC)[C@H](O)C2)[C@H](C)O[C@@H]1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(O[C@@H]3O[C@@H](C)[C@@H](OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)[C@@H](O)C3)C2(O)C#C\C=C/C#C1 PEIYAHAOJOISPN-WCXFNBEESA-N 0.000 abstract description 3
- LJQQFQHBKUKHIS-KSFFZXMPSA-N esperamicin A1 Chemical compound O1C[C@H](NC(C)C)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](O)[C@H](NO[C@@H]2O[C@H](C)[C@@H](SC)[C@@H](O)C2)[C@@H](C)O[C@H]1O[C@H]1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@H](OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)[C@@]2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-KSFFZXMPSA-N 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 11
- 230000000845 anti-microbial effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229930189413 Esperamicin Natural products 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 238000010265 fast atom bombardment Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- 241000187362 Actinomadura Species 0.000 description 2
- 101150034980 BRDT gene Proteins 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 2
- 229910000355 cerium(IV) sulfate Inorganic materials 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000187361 Actinomadura sp. Species 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010042309 Netropsin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001221452 Staphylococcus faecalis Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- GTOWDLHXRPBZKU-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl.ClC(Cl)Cl GTOWDLHXRPBZKU-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- -1 methyl glycosides Chemical class 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- AUJXLBOHYWTPFV-RQLJINDISA-N n-[(4s,7r,11s,17s,20r,24s)-2,4,12,15,17,25-hexamethyl-29-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-7-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-20-yl]quinoxaline-2-carboxamide Chemical compound C([C@H](C(=O)N[C@@H](C)C(=O)N1C)NC(=O)C=2N=C3C=CC=CC3=NC=2)OC(=O)[C@H](C(C)C)N(C)C(=O)C2N(C)C(=O)[C@H](C)NC(=O)[C@H](NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)[C@H](C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-RQLJINDISA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RAGFPHFDFVNLCG-INYQBOQCSA-N sibiromycin Chemical compound O[C@@H]1[C@@](O)(C)[C@@H](NC)[C@H](C)O[C@H]1OC(C(=C1O)C)=CC(C2=O)=C1N[C@H](O)[C@H]1N2C=C(\C=C\C)C1 RAGFPHFDFVNLCG-INYQBOQCSA-N 0.000 description 1
- RAGFPHFDFVNLCG-UHFFFAOYSA-N sibiromycin Natural products OC1C(O)(C)C(NC)C(C)OC1OC(C(=C1O)C)=CC(C2=O)=C1NC(O)C1N2C=C(C=CC)C1 RAGFPHFDFVNLCG-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/03—Actinomadura
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77033585A | 1985-08-27 | 1985-08-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE862280L IE862280L (en) | 1987-02-27 |
| IE59204B1 true IE59204B1 (en) | 1994-01-26 |
Family
ID=25088206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE228086A IE59204B1 (en) | 1985-08-27 | 1986-08-26 | Antibiotics |
Country Status (26)
| Country | Link |
|---|---|
| JP (2) | JPH0733393B2 (da) |
| KR (1) | KR920010226B1 (da) |
| AT (1) | AT392971B (da) |
| AU (1) | AU604464B2 (da) |
| BE (1) | BE905332A (da) |
| CA (1) | CA1307256C (da) |
| CH (1) | CH668598A5 (da) |
| CY (1) | CY1676A (da) |
| DE (1) | DE3629052C2 (da) |
| DK (1) | DK170671B1 (da) |
| ES (1) | ES2002728A6 (da) |
| FI (1) | FI83422C (da) |
| FR (1) | FR2586686B1 (da) |
| GB (1) | GB2179649A (da) |
| GR (1) | GR862160B (da) |
| HK (1) | HK793A (da) |
| HU (1) | HU197915B (da) |
| IE (1) | IE59204B1 (da) |
| IL (1) | IL79519A0 (da) |
| IT (1) | IT1229176B (da) |
| LU (1) | LU86562A1 (da) |
| NL (1) | NL8602165A (da) |
| PT (1) | PT83261B (da) |
| SE (2) | SE469632B (da) |
| SG (1) | SG109692G (da) |
| ZA (1) | ZA865796B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE219096T1 (de) * | 1987-01-30 | 2002-06-15 | American Cyanamid Co | Dihydroderivate der antibiotika vom typ ll-e33288 |
| US4916065A (en) * | 1988-06-10 | 1990-04-10 | Bristol-Myers Company | BU-3420T Antitumor antibiotic |
| US5086045A (en) * | 1989-03-15 | 1992-02-04 | Bristol-Myers Squibb Company | Antitumor antibiotic |
| US5028536A (en) * | 1989-03-15 | 1991-07-02 | Bristol-Myers Squibb Company | Antitumor antibiotic BMY-41339 |
| CA2027601A1 (en) * | 1989-11-06 | 1991-05-07 | Koko Sugawara | Antitumor antibiotic bu-3983t |
| CA2039789A1 (en) * | 1990-04-27 | 1991-10-28 | Samuel J. Danishefsky | Calicheamicinone, derivatives and analogs thereof and methods of making the same |
| US5116845A (en) * | 1990-05-04 | 1992-05-26 | Bristol-Myers Company | BU-3420T antitumor antibiotic |
| US5264586A (en) * | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3148023A1 (de) * | 1981-12-04 | 1983-06-09 | Rudolf Dipl.-Ing. 8901 Oberottmarshausen Fischer | Heizungskessel fuer heisse rauchgase |
| US4578271A (en) * | 1982-05-24 | 1986-03-25 | Fujisawa Pharmaceutical Co., Ltd. | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions |
| NZ208013A (en) * | 1983-05-16 | 1987-07-31 | Bristol Myers Co | Antitumour antibiotic bbm-1675 and production by cultivating actinomadura verrucosospora |
| JPS606194A (ja) * | 1983-06-23 | 1985-01-12 | Meiji Seika Kaisha Ltd | 新規抗生物質ｓｆ−２２８８及びその製造法 |
| US4530835A (en) * | 1983-07-08 | 1985-07-23 | Warner-Lambert Company | CL-1577 Antibiotic compounds and their production |
-
1986
- 1986-07-25 IL IL79519A patent/IL79519A0/xx not_active IP Right Cessation
- 1986-08-01 ZA ZA865796A patent/ZA865796B/xx unknown
- 1986-08-15 CA CA000516111A patent/CA1307256C/en not_active Expired - Fee Related
- 1986-08-19 GB GB08620118A patent/GB2179649A/en active Granted
- 1986-08-20 GR GR862160A patent/GR862160B/el unknown
- 1986-08-22 FI FI863405A patent/FI83422C/fi not_active IP Right Cessation
- 1986-08-22 AU AU61751/86A patent/AU604464B2/en not_active Ceased
- 1986-08-26 IT IT8621527A patent/IT1229176B/it active
- 1986-08-26 SE SE8603597A patent/SE469632B/sv not_active IP Right Cessation
- 1986-08-26 FR FR868612085A patent/FR2586686B1/fr not_active Expired - Fee Related
- 1986-08-26 ES ES8601355A patent/ES2002728A6/es not_active Expired
- 1986-08-26 IE IE228086A patent/IE59204B1/en not_active IP Right Cessation
- 1986-08-26 NL NL8602165A patent/NL8602165A/nl not_active Application Discontinuation
- 1986-08-26 DK DK406086A patent/DK170671B1/da not_active IP Right Cessation
- 1986-08-26 LU LU86562A patent/LU86562A1/fr unknown
- 1986-08-26 KR KR1019860007092A patent/KR920010226B1/ko not_active IP Right Cessation
- 1986-08-26 CH CH3417/86A patent/CH668598A5/de not_active IP Right Cessation
- 1986-08-26 BE BE0/217084A patent/BE905332A/fr not_active IP Right Cessation
- 1986-08-27 DE DE3629052A patent/DE3629052C2/de not_active Expired - Fee Related
- 1986-08-27 JP JP61201199A patent/JPH0733393B2/ja not_active Expired - Lifetime
- 1986-08-27 AT AT2317/86A patent/AT392971B/de not_active IP Right Cessation
- 1986-08-27 PT PT83261A patent/PT83261B/pt unknown
- 1986-08-27 HU HU863709A patent/HU197915B/hu not_active IP Right Cessation
-
1992
- 1992-02-13 SE SE9200428A patent/SE9200428L/xx not_active Application Discontinuation
- 1992-10-16 SG SG1096/92A patent/SG109692G/en unknown
-
1993
- 1993-01-07 HK HK7/93A patent/HK793A/xx not_active IP Right Cessation
- 1993-10-10 CY CY1676A patent/CY1676A/xx unknown
-
1994
- 1994-08-19 JP JP6195156A patent/JPH07233186A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kiyoto et al. | A NEW ANTITUMOR ANTIBIOTIC, FR-900482 II. PRODUCTION, ISOLATION, CHARACTERIZATION AND BIOLOGICAL ACTIVITY | |
| US4518589A (en) | BBM-2478 Antibiotic complex | |
| US4837206A (en) | Esperamicin derivatives | |
| DK145200B (da) | Fremgangsmaade til fremstilling af anthtacyclinglycosid-antibiotika | |
| IE59204B1 (en) | Antibiotics | |
| US4921700A (en) | BBM-1675c and d antitumor antibiotics | |
| EP0871638B1 (en) | Novel aminooligosaccharide derivative and process for preparing the same | |
| US4847387A (en) | Antibiotic compounds DC-92B and DC-92D | |
| HU202591B (en) | Process for producing antibiotic bu-3420t and pharmaceutical composition comprising such antibiotic | |
| DK146282B (da) | Fremgangsmaade til fremstilling af anthracyclin-glycosid-antibiotika, kaldet rhodirubin a og b eller salte eller deoxyribonukleinsyrekomplekser deraf | |
| EP0110155A1 (en) | Novel anthracycline derivatives, a process for preparing the same by a microorganism strain, the novel strain streptomyces cyaneus, and use of the anthracycline derivatives as medicaments | |
| KR100862546B1 (ko) | 칼로포로사이드 유도체, 이의 제조방법 및 이를 포함하는 의약 | |
| US4572895A (en) | Process for preparing an antibiotic complex by culturing actinomyces strain ATCC 39417 | |
| HU193928B (en) | Process for preparing anticarcinogen antibiotics bbm-1675 | |
| US5091523A (en) | Mitomycin derivatives having reduced bone marrow toxicity, processes for their preparation, and the uses thereof | |
| US5837691A (en) | Actinomadura vulgaris subsp vulgaris and antimicrobial complex and antimicrobial | |
| US4241182A (en) | Fortimicin factors KG1, KG2 and KG3 and processes for production thereof | |
| EP0311054B1 (en) | Anthracycline Antibiotics | |
| FI90991B (fi) | Menetelmä kasvainten vastaisen antibiootin BU-3862T valmistamiseksi | |
| EP0447494A1 (en) | Altromycin compounds | |
| EP0423247B1 (en) | Coumamidine compounds | |
| EP0711785A1 (en) | Novel antitumor antibiotic compounds: hayumicins and analogs thereof | |
| CA2041815A1 (en) | Altromycin compounds | |
| HUT65555A (en) | Process for c-11 modified pradimicin derivatives and pharmaceutical compositions containing them | |
| JPH06184184A (ja) | 新規なプラジミシン族抗生物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |